<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399410</url>
  </required_header>
  <id_info>
    <org_study_id>UGHENT</org_study_id>
    <nct_id>NCT02399410</nct_id>
  </id_info>
  <brief_title>Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis</brief_title>
  <official_title>BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Bev-IP trial is designed to assess the feasibility and efficacy of a combined treatment
      consisting of perioperative combination chemotherapy with the vascular endothelial growth
      factor A inhibitor bevacizumab and cytoreductive surgery with intraperitoneal oxaliplatin.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>surgical morbidity and mortality</measure>
    <time_frame>until 3 months after surgery and intraperitoneal chemotherapy</time_frame>
    <description>This will be estimated with the Dindo-Clavien classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>24 months after finishing the adjuvant chemotherapy</time_frame>
    <description>time interval between date of surgery and disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months after finishing the adjuvant chemotherapy</time_frame>
    <description>calculated from date of surgery until death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment completion rate</measure>
    <time_frame>day 1 after termination of adjuvant chemotherapy</time_frame>
    <description>percentage of patients receiving all planned courses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chemotherapy-related toxicity</measure>
    <time_frame>1 month after termination of the adjuvant chemotherapy</time_frame>
    <description>percentage of patients experiencing chemotherapy-related toxicity will be assessed using the Common Terminology Criteria for Adverse Events (NCI-CTCAE) scoring system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological gross response of peritoneal tumour deposits to neoadjuvant combination chemotherapy with bevacizumab</measure>
    <time_frame>day 1 after termination of the cytoreductive surgery</time_frame>
    <description>will be scored with a 3 level regression scale</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>bevacizumab and CRS with oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perioperative chemotherapy plus bevacizumab and CRS with oxaliplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perioperative chemotherapy plus bevacizumab</intervention_name>
    <description>preoperative and postoperative combination chemotherapy with bevacizumab</description>
    <arm_group_label>bevacizumab and CRS with oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cytoreductive surgery</intervention_name>
    <description>complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.</description>
    <arm_group_label>bevacizumab and CRS with oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intraperitoneal Oxaliplatin</intervention_name>
    <description>Pump-driven intraperitoneal administration of oxaliplatin</description>
    <arm_group_label>bevacizumab and CRS with oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  biopsy proven adenocarcinoma of the colon or rectum and synchronous or metachronous
             peritoneal carcinomatosis.

          -  absence of systemic disease, with the exception of small, superficial liver
             metastases, requiring only minor surgery.

          -  resectable disease at staging, during laparoscopic evaluation and during exploration
             for cytoreductive surgery and intraperitoneal chemotherapy.

          -  complete macroscopic cytoreduction at the time of surgery (CC-0/1)

          -  good general health status (Karnofsky index &gt; 70%)

          -  expected life expectancy more than 6 months

          -  no other malignancy than disease under study

          -  serum creatinine &lt; 1.5 mg/dl or a calculated GFR ≥ 60 mL/min/1.73 m

          -  serum total bilirubin &lt; 1.5 mg/dl

          -  platelet count &gt; 100,000/ml

          -  hemoglobin &gt; 9g/dl

          -  neutrophil granulocytes &gt; 1,500/ml

          -  International Normalized Ration (INR) 2 or &lt; 2

          -  Absence of alcohol and/or drug abuse

          -  No inclusion in other clinical trials interfering with the study protocol

          -  No concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not
             indicated in the study protocol

          -  Absence of heart failure (NYHA 2 or &gt; 2) or significant coronary artery disease

          -  No pregnancy or breast feeding

          -  Adequate contraception in fertile patients

        Exclusion Criteria:

          -  No written informed consent

          -  tumour in the presence of obstruction

          -  evidence of extra-abdominal disease or extensive liver metastasis

          -  peritoneal cancer index &gt; 25

          -  active bacterial, viral or fungal infection

          -  active gastro-duodenal ulcer

          -  parenchymal liver disease (any stage cirrhosis)

          -  uncontrolled diabetes mellitus

          -  severe obstructive or restrictive respiratory insufficiency

          -  psychiatric pathology capable of affecting comprehension and judgment faculty

          -  Known allergy to oxaliplatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim P Ceelen, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wim P Ceelen, MD,PhD</last_name>
    <phone>+32 9 332 62 51</phone>
    <email>wim.ceelen@ugent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wouter CI Willaert, MD</last_name>
    <phone>+32 9 332 89 50</phone>
    <email>wouter.willaert@ugent.be</email>
  </overall_contact_backup>
  <reference>
    <citation>Herszényi L, Tulassay Z. Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):249-58. Review.</citation>
    <PMID>20496531</PMID>
  </reference>
  <reference>
    <citation>Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice. Cancer Treat Rev. 2012 Aug;38(5):397-406. doi: 10.1016/j.ctrv.2011.08.002. Epub 2011 Sep 6. Review.</citation>
    <PMID>21899955</PMID>
  </reference>
  <reference>
    <citation>Klaver YL, Simkens LH, Lemmens VE, Koopman M, Teerenstra S, Bleichrodt RP, de Hingh IH, Punt CJ. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012 Jul;38(7):617-23. doi: 10.1016/j.ejso.2012.03.008. Epub 2012 May 8.</citation>
    <PMID>22572106</PMID>
  </reference>
  <reference>
    <citation>Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006 Feb;243(2):212-22. Review.</citation>
    <PMID>16432354</PMID>
  </reference>
  <reference>
    <citation>Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012 May;99(5):699-705. doi: 10.1002/bjs.8679. Epub 2012 Jan 27.</citation>
    <PMID>22287157</PMID>
  </reference>
  <reference>
    <citation>Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011 Jun 1;128(11):2717-25. doi: 10.1002/ijc.25596. Epub 2010 Oct 13.</citation>
    <PMID>20715167</PMID>
  </reference>
  <reference>
    <citation>Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011 Oct 15;117(20):4623-32. doi: 10.1002/cncr.26086. Epub 2011 Mar 31.</citation>
    <PMID>21456008</PMID>
  </reference>
  <reference>
    <citation>Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, François Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000 Jan 15;88(2):358-63.</citation>
    <PMID>10640968</PMID>
  </reference>
  <reference>
    <citation>Pelz JO, Chua TC, Esquivel J, Stojadinovic A, Doerfer J, Morris DL, Maeder U, Germer CT, Kerscher AG. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer. 2010 Dec 22;10:689. doi: 10.1186/1471-2407-10-689.</citation>
    <PMID>21176206</PMID>
  </reference>
  <reference>
    <citation>Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20;30(3):263-7. doi: 10.1200/JCO.2011.37.1039. Epub 2011 Dec 12.</citation>
    <PMID>22162570</PMID>
  </reference>
  <reference>
    <citation>Euler J, Priesching A, Wenzl J, Sauermann G, Klöckler K, Kretschmer G. [Hyperthermic peritoneal perfusion in ascites tumours in rats (author's transl)]. Wien Klin Wochenschr. 1974 Apr 19;86(8):220-5. German.</citation>
    <PMID>4822331</PMID>
  </reference>
  <reference>
    <citation>Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980 Feb;40(2):256-60.</citation>
    <PMID>6766084</PMID>
  </reference>
  <reference>
    <citation>Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R, Riess H. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002 Jul;43(1):33-56. Review.</citation>
    <PMID>12098606</PMID>
  </reference>
  <reference>
    <citation>Raaphorst GP, Yang DP. The evaluation of thermal cisplatin sensitization in normal and XP human cells using mild hyperthermia at 40 and 41 degrees C. Anticancer Res. 2005 Jul-Aug;25(4):2649-53.</citation>
    <PMID>16080507</PMID>
  </reference>
  <reference>
    <citation>Los G, Sminia P, Wondergem J, Mutsaers PH, Havemen J, ten Bokkel Huinink D, Smals O, Gonzalez-Gonzalez D, McVie JG. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer. 1991;27(4):472-7.</citation>
    <PMID>1827723</PMID>
  </reference>
  <reference>
    <citation>Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003 Oct 15;21(20):3737-43.</citation>
    <PMID>14551293</PMID>
  </reference>
  <reference>
    <citation>Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008 Sep;15(9):2426-32. doi: 10.1245/s10434-008-9966-2. Epub 2008 Jun 3.</citation>
    <PMID>18521686</PMID>
  </reference>
  <reference>
    <citation>Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004 Aug 15;22(16):3284-92.</citation>
    <PMID>15310771</PMID>
  </reference>
  <reference>
    <citation>Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006 Aug 20;24(24):4011-9. Review.</citation>
    <PMID>16921055</PMID>
  </reference>
  <reference>
    <citation>Hompes D, D'Hoore A, Van Cutsem E, Fieuws S, Ceelen W, Peeters M, Van der Speeten K, Bertrand C, Legendre H, Kerger J. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Ann Surg Oncol. 2012 Jul;19(7):2186-94. doi: 10.1245/s10434-012-2264-z. Epub 2012 Mar 7.</citation>
    <PMID>22395983</PMID>
  </reference>
  <reference>
    <citation>Cavaliere F, De Simone M, Virzì S, Deraco M, Rossi CR, Garofalo A, Di Filippo F, Giannarelli D, Vaira M, Valle M, Pilati P, Perri P, La Pinta M, Monsellato I, Guadagni F. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur J Surg Oncol. 2011 Feb;37(2):148-54. doi: 10.1016/j.ejso.2010.10.014. Epub 2010 Nov 18.</citation>
    <PMID>21093205</PMID>
  </reference>
  <reference>
    <citation>Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goéré D, Bonastre J. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009 Feb 10;27(5):681-5. doi: 10.1200/JCO.2008.19.7160. Epub 2008 Dec 22.</citation>
    <PMID>19103728</PMID>
  </reference>
  <reference>
    <citation>Quenet F, Goéré D, Mehta SS, Roca L, Dumont F, Hessissen M, Saint-Aubert B, Elias D. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011 Aug;254(2):294-301. doi: 10.1097/SLA.0b013e3182263933.</citation>
    <PMID>21772129</PMID>
  </reference>
  <reference>
    <citation>Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ 3rd. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010 Aug 15;116(16):3756-62. doi: 10.1002/cncr.25116.</citation>
    <PMID>20564081</PMID>
  </reference>
  <reference>
    <citation>Cashin PH, Graf W, Nygren P, Mahteme H. Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis: prognosis and treatment of recurrences in a cohort study. Eur J Surg Oncol. 2012 Jun;38(6):509-15. doi: 10.1016/j.ejso.2012.03.001. Epub 2012 Apr 3.</citation>
    <PMID>22475555</PMID>
  </reference>
  <reference>
    <citation>Shen P, Hawksworth J, Lovato J, Loggie BW, Geisinger KR, Fleming RA, Levine EA. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol. 2004 Feb;11(2):178-86.</citation>
    <PMID>14761921</PMID>
  </reference>
  <reference>
    <citation>Vaira M, Cioppa T, D'Amico S, de Marco G, D'Alessandro M, Fiorentini G, De Simone M. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years. In Vivo. 2010 Jan-Feb;24(1):79-84.</citation>
    <PMID>20133981</PMID>
  </reference>
  <results_reference>
    <citation>Ceelen W, Van Nieuwenhove Y, Putte DV, Pattyn P. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ann Surg Oncol. 2014 Sep;21(9):3023-8. doi: 10.1245/s10434-014-3713-7. Epub 2014 Apr 23.</citation>
    <PMID>24756812</PMID>
  </results_reference>
  <results_reference>
    <citation>Tamsma JT, Keizer HJ, Meinders AE. Pathogenesis of malignant ascites: Starling's law of capillary hemodynamics revisited. Ann Oncol. 2001 Oct;12(10):1353-7. Review.</citation>
    <PMID>11762804</PMID>
  </results_reference>
  <results_reference>
    <citation>Welch S, Spithoff K, Rumble RB, Maroun J; Gastrointestinal Cancer Disease Site Group. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2010 Jun;21(6):1152-62. doi: 10.1093/annonc/mdp533. Epub 2009 Nov 25. Review.</citation>
    <PMID>19942597</PMID>
  </results_reference>
  <results_reference>
    <citation>Olsen MW, Ley CD, Junker N, Hansen AJ, Lund EL, Kristjansen PE. Angiopoietin-4 inhibits angiogenesis and reduces interstitial fluid pressure. Neoplasia. 2006 May;8(5):364-72.</citation>
    <PMID>16790085</PMID>
  </results_reference>
  <results_reference>
    <citation>Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM. Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res. 2006 Feb 1;66(3):1434-45.</citation>
    <PMID>16452199</PMID>
  </results_reference>
  <results_reference>
    <citation>Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb;10(2):145-7. Epub 2004 Jan 25. Erratum in: Nat Med. 2004 Jun;10(6):649.</citation>
    <PMID>14745444</PMID>
  </results_reference>
  <results_reference>
    <citation>Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist. 2009 Dec;14(12):1242-51. doi: 10.1634/theoncologist.2009-0109. Epub 2009 Dec 11. Review.</citation>
    <PMID>20008305</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>March 20, 2015</last_update_submitted>
  <last_update_submitted_qc>March 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Ghent</investigator_affiliation>
    <investigator_full_name>GIHeelkunde</investigator_full_name>
    <investigator_title>Wim P Ceelen, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>cytoreductive surgery</keyword>
  <keyword>hipec</keyword>
  <keyword>perioperative chemotherapy</keyword>
  <keyword>peritoneal carcinomatosis</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>colorectal surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

